Literature DB >> 24615647

Is carcinoma in situ a precursor lesion of invasive breast cancer?

Teresa To1, Claus Wall, Cornelia J Baines, Anthony B Miller.   

Abstract

This study measures the probability of development of invasive breast cancer (BC) following the diagnosis of carcinomas in situ (CIS). A 25-year prospective follow-up was conducted by linking the Canadian National Breast Screening Study (CNBSS) to cancer registries and a national vital statistics database. Subsequent BC incidence was identified in CNBSS women who were diagnosed with CIS. CIS was classified into ductal (DCIS) and lobular carcinoma in situ (LCIS). Cumulative cancer incidence probabilities were calculated and a 1:5 matched nested case control study was conducted to estimate the odds of BC development. Of the 146 women diagnosed with CIS, 26 developed invasive BC (17.8%) and 12 died of BC (8.2%). The average time from the diagnosis of CIS to invasive BC was 6.3 years (± 5.6). The 20-year cumulative incidence probabilities for DCIS and LCIS were 19.0% (95%CI: 11.2, 26.8) and 21.3% (95%CI: 7.1, 35.4) respectively. The odds of development of BC in CIS women was significantly elevated compared with controls (OR = 2.6, 95% CI: 1.5, 4.5). While women with CIS had a higher odds of development of BC compared to those without CIS, at 20-year post CIS diagnosis, more than 80% of them remained free of invasive BC. This low probability of developing invasive BC post CIS diagnosis does not support the notion that CIS of the breast is an obligate precursor lesion of invasive BC.
© 2014 UICC.

Entities:  

Keywords:  cancer incidence; carcinoma in situ of the breast; precursor lesion

Mesh:

Year:  2014        PMID: 24615647     DOI: 10.1002/ijc.28803

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

2.  Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.

Authors:  Carla Cedolini; Serena Bertozzi; Ambrogio P Londero; Luca Seriau; Michela Andretta; Diane Agakiza; Sandro Fongione; Alessandro Uzzau; Andrea Risaliti
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Genetic risk variants associated with in situ breast cancer.

Authors:  Daniele Campa; Myrto Barrdahl; Mia M Gaudet; Amanda Black; Stephen J Chanock; W Ryan Diver; Susan M Gapstur; Christopher Haiman; Susan Hankinson; Aditi Hazra; Brian Henderson; Robert N Hoover; David J Hunter; Amit D Joshi; Peter Kraft; Loic Le Marchand; Sara Lindström; Walter Willett; Ruth C Travis; Pilar Amiano; Afshan Siddiq; Dimitrios Trichopoulos; Malin Sund; Anne Tjønneland; Elisabete Weiderpass; Petra H Peeters; Salvatore Panico; Laure Dossus; Regina G Ziegler; Federico Canzian; Rudolf Kaaks
Journal:  Breast Cancer Res       Date:  2015-06-13       Impact factor: 6.466

4.  Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis.

Authors:  Xining Zhang; Hongji Dai; Ben Liu; Fengju Song; Kexin Chen
Journal:  Eur J Cancer Prev       Date:  2016-01       Impact factor: 2.497

Review 5.  Molecular drivers of lobular carcinoma in situ.

Authors:  Greg J Logan; David J Dabbs; Peter C Lucas; Rachel C Jankowitz; Daniel D Brown; Beth Z Clark; Steffi Oesterreich; Priscilla F McAuliffe
Journal:  Breast Cancer Res       Date:  2015-06-04       Impact factor: 6.466

6.  Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.

Authors:  Louisa Lisa Lo; Roger Laughlin Milne; Yuyan Liao; Jack Cuzick; Mary Beth Terry; Kelly-Anne Phillips
Journal:  Br J Cancer       Date:  2018-06-21       Impact factor: 7.640

7.  Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study.

Authors:  Lindsay A Williams; Patricia Casbas-Hernandez; Hazel B Nichols; Chiu Kit Tse; Emma H Allott; Lisa A Carey; Andrew F Olshan; Melissa A Troester
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

8.  The OncoSim-Breast Cancer Microsimulation Model.

Authors:  Jean H E Yong; Claude Nadeau; William M Flanagan; Andrew J Coldman; Keiko Asakawa; Rochelle Garner; Natalie Fitzgerald; Martin J Yaffe; Anthony B Miller
Journal:  Curr Oncol       Date:  2022-03-03       Impact factor: 3.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.